The clinical research affiliate of the Lupus Research Alliance, Lupus Therapeutics, announced a partnership with AbbVie Inc. for the Phase 3 development of upadacitinib (RINVOQ®) as a potential treatment for people living with systemic lupus erythematosus (SLE). Lupus Therapeutics will assist with recruiting participants to join the study, activation of each study site and engaging sites to join the study through the Lupus Clinical Investigators Network (LuCIN) of top academic centers throughout North America.

The full press release is available on the Lupus Therapeutics website.

Read full Press Release